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Imbalance of neurotrophin receptor isoforms
TrkB-FL/TrkB-T1 induces neuronal death in
excitotoxicity
O´G Vidaurre1,7, S Gasco´n1,3,7, R Deogracias1,4, M Sobrado1,5, E Cuadrado2,6, J Montaner2, A´ Rodrı´guez-Pen˜a1 and M Dı´az-Guerra*,1
A better understanding of the mechanisms underlying neuronal death in cerebral ischemia is required for the development of
stroke therapies. Here we analyze the contribution of the tropomyosin-related kinase B (TrkB) neurotrophin receptor to
excitotoxicity, a primary pathological mechanism in ischemia, which is induced by overstimulation of glutamate receptors of the
N-methyl-D-aspartate type. We demonstrate a significant modification of TrkB expression that is strongly associated with
neurodegeneration in models of ischemia and in vitro excitotoxicity. Two mechanisms cooperate for TrkB dysregulation:
(1) calpain-processing of full-length TrkB (TrkB-FL), high-affinity receptor for brain-derived neurotrophic factor, which produces
a truncated protein lacking the tyrosine-kinase domain and strikingly similar to the inactive TrkB-T1 isoform and (2) reverse
regulation of the mRNA of these isoforms. Collectively, excitotoxicity results in a decrease of TrkB-FL, the production of
truncated TrkB-FL and the upregulation of TrkB-T1. A similar neuro-specific increase of the TrkB-T1 isoform is also observed in
stroke patients. A lentivirus designed for both neuro-specific TrkB-T1 interference and increased TrkB-FL expression allows
recovery of the TrkB-FL/TrkB-T1 balance and protects neurons from excitotoxic death. These data implicate a combination of
TrkB-FL downregulation and TrkB-T1 upregulation as significant causes of neuronal death in excitotoxicity, and reveal novel
targets for the design of stroke therapies.
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Stroke is a leading cause of death, dementia, and adult
disability. The available therapies are insufficient to restrict
brain damage; therefore, we need to understand the
mechanisms underlying neuronal death in those regions
surrounding the infarct. A primary pathological mechanism in
ischemia is excitotoxicity, a form of neuronal death induced by
overactivation of the N-methyl-D-aspartate (NMDA)-type of
glutamate receptors (NMDARs), also associated with other
acute disorders or neurodegenerative diseases.1 Nonethe-
less, efforts to inhibit NMDARs have generally failed, mainly
due to the critical role these receptors have in neuronal
survival,2,3 synaptic plasticity, learning, and memory.4 Pro-
survival signaling initiated by synaptic NMDARs includes
induction of antioxidant defenses,5 activation of extracellular
signal-regulated kinase,6 and phosphorylation of the cAMP
response element-binding protein (CREB), which results in
the expression of brain-derived neurotrophic factor (BDNF)7,8
and its receptor, tropomyosin-related kinase B (TrkB).9,10
Pathological activation of NMDARs opposes these effects
by coupling Ca2þ -influx to mitochondrial dysfunction and
neuronal death pathways.2,11 Additionally, NMDAR
overactivation also disrupts critical survival pathways by
uncoupling synaptic NMDARs from cytoskeletal proteins
and pro-survival signaling. Transcriptional downregulation of
the NMDAR subunit, GluN1,12 and calpain-processing of the
GluN2 subunits13,14 and NMDAR-interacting proteins13,15 in
excitotoxicity and ischemia have been demonstrated. Calpain
is an effector of Ca2þ -overload central to ischemia acting as a
modulatory protease that transforms substrate stability,
location, or activity.16
Processes downstream of the NMDAR overactivation,
which are aberrant in stroke, might constitute novel ther-
apeutic targets for reduction of neuronal death. We hypothe-
sized that neurotrophin receptors, which are associated with
NMDARs,17,18 are modified by ischemia as other NMDAR-
related proteins. Although neurotrophins have been proposed
as therapeutic agents for stroke and excitotoxicity-associated
diseases,19 the effect of ischemia on neurotrophin signaling is
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largely unknown. These molecules are fundamental for the
development of adult nervous system. Among them, BDNF
has a major role through binding to its high-affinity tyrosine-
kinase receptor, TrkB, and initation of signaling cascades that
regulate gene expression, neuronal survival, neurotransmitter
release, and synaptic transmission.20 In addition to the
full-length isoform (TrkB-FL) encoding the active receptor,
alternative splicing yields receptors that lack the kinase
domain, TrkB-T1, TrkB-T2, and TrkB-T-Shc,21 suggested as
involved in TrkB-FL modulation.22 Particularly, TrkB-T1
opposes TrkB-FL function23,24 via competition for BDNF
binding21 or the formation of inactive heterodimers.25
Additionally, TrkB-FL-independent signaling has been also
suggested for TrkB-T1.26
We were interested in the identification of additional
neuronal survival pathways downregulated in stroke and
sought to characterize their contribution to excitotoxicity.
Therefore, we analyzed TrkB expression in models of
ischemia and excitotoxicity, and characterized mechanisms
acting at the mRNA and protein levels yielding TrkB-FL
downregulation and TrkB-T1 upregulation. We investigated
the contribution of this imbalance to excitotoxicity and
ischemia, and demonstrated a strong association with
neurodegeneration. Analysis of human necropsies suggested
that TrkB levels might be similarly altered by stroke. These
results identified the TrkB isoforms as new therapeutic targets
for neuroprotection against excitotoxicity.
Results
Opposite regulation of TrkB isoforms in a model of
ischemia. To identify the neuronal survival pathways
downregulated in ischemia, we analyzed the TrkB
expression and neurodegeneration in a rat model of focal
cerebral ischemia, induced by a 1-h middle cerebral artery
occlusion (MCAO), followed by reperfusion for 6 h. These
conditions produced a moderate decrease in Nissl staining in
this artery territory (Supplementary Figure S1) and
allowed TrkB characterization in neurons committed to die,
whereas avoiding massive death starting after 24 h of
reperfusion.12,13,27 Immunohistochemistry with isoform-
specific antibodies revealed high TrkB-T1 levels in NeuN-
labeled neurons in the ischemic region compared with very
low expression in equivalent regions of contralateral
neocortex (Figure 1A). Analysis of glial fibrillary acidic
protein (Supplementary Figures S2A and B) demonstrated
Figure 1 Transient cerebral ischemia induces the opposite regulation of
TrkB-FL and T1 isoforms in rat neurons, and TrkB-T1 upregulation is associated
with neurodegeneration. Double immunohistochemistry with isoform-specific
antibodies of coronal sections of animals subjected to MCAO followed by blood
reperfusion (6 h), a model in which damage is limited to the cortex, revealed that
neurons in the ischemic region present a large increase in TrkB-T1 levels compared
with those in the contralateral hemisphere (A) and an important decrease of TrkB-
FL expression (B). Combined immunostaining of TrkB-T1 and NeuN with Fluoro-
Jade B (FJB) labeling demonstrated a dramatic association of TrkB-T1 upregulation
in the ischemic region with early neuronal degeneration (arrows) (C). However,
there was a small number of neurons in this area which did not express TrkB-T1 or
stain with FJB (arrowheads). Representative confocal microscopy images
corresponding to single sections are shown. The scale bars represent 10 mm
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scarce astrocytic staining in the ischemic area at this early
time and no TrkB-T1 upregulation in glial cells. It was
important to establish the cells where TrkB-T1 increased,
because this isoform is expressed in neurons and glial
cells.28 Immunostaining with a TrkB-FL antibody demon-
strated a dramatic reduction of the receptor in the ischemic
area compared with the high levels found in neurons in the
contralateral region (Figure 1B). The presence of neurons in
the ischemic region was demonstrated with NeuN-labeling,
which confirmed that TrkB-FL decrease was not due to
neuronal death. The switch in TrkB expression from mostly
TrkB-FL in contralateral regions to TrkB-T1 in ischemic tissue
justified the labeling of both areas with an antibody directed
to an epitope present in all TrkB isoforms (panTrkB;
Supplementary Figures S2C and D). Finally, to investigate
a possible association between TrkB-T1 expression
and neurodegeneration, we combined immunostaining for
TrkB-T1 and NeuN with Fluoro-Jade B-labeling, a compound
that specifically binds to degenerating neurons. In the
ischemic area, a dramatic association of high levels of
TrkB-T1 expression with neurons undergoing degeneration
was observed (Figure 1C, arrows).
Neuronal-specific TrkB regulation is induced by
excitotoxicity. Excitotoxicity is a primary pathological
mechanism of neurodegeneration in stroke.1 We investi-
gated if excitotoxicity might be causing the TrkB-FL/TrkB-T1
imbalance by using a model reproducing in vitro the
pathological activation of glutamate receptors. Primary
cultures of rat cortices grown 14 days in vitro (DIV) were
incubated with high concentrations (100 mM) of NMDA or
glutamate for 2 h, conditions of relatively high-neuronal
viability (Supplementary Figure S3). The NMDAR agonists
induced a significant decrease in TrkB-FL (145 kDa) and a
reciprocal increase in the truncated forms (collectively
designated as tTrkB), as shown by panTrkB (Figure 2A).
Other neuronal proteins such as the neuronal-specific
enolase (NSE) were not modified by treatment, which
demonstrated that TrkB regulation is specific and not a
consequence of massive cell death. These effects required
the specific activation of NMDARs and were blocked by
competitive (DL-AP5) or non-competitive (memantine,
Figure 2 Neuronal-specific regulation of TrkB is induced by NMDAR
overactivation in a cellular model of excitotoxicity. (A) Opposite regulation of the
TrkB isoforms was induced by agonists of glutamate receptors and prevented by
specific NMDAR antagonists. Primary cortical cultures (14 DIV) were treated with
NMDA (100mM) or glutamate (100mM) with their co-agonist glycine (10 mM) for 2 h,
with or without the antagonists DL-AP5 (200mM), memantine (10mM), or ketamine
(500mM). TrkB-FL and the other truncated isoforms (tTrkB) that are recognized by
panTrkB are indicated. (B) Time course of the TrkB-FL decrease and the tTrkB
or TrkB-T1 increase in cultures treated with NMDA for the indicated times.
(C) Quantitation of TrkB dysregulation. Relative protein levels of TrkB-FL, tTrkB, or
TrkB-T1 (mean±S.E.M., n¼ 4 experiments) were established after normalization
to NSE and comparison with the protein levels in untreated cells, which were
arbitrarily assigned a value of 100%. The effect of NMDA was assessed using a
Student’s unpaired t-test (*Po0.05, **Po0.01, and ***Po0.001). (D) Double
immunofluorescence of cultures stimulated with NMDA for 1 h using panTrkB or
neuronal-specific antibodies demonstrated the neuronal specificity of TrkB
expression (arrows) and the lack of TrkB staining in glial cells in the culture
(arrowheads). Analysis with isoform-specific antibodies was not possible, because
they produced very weak immunofluorescent signals. Representative confocal
microscopy images corresponding to single sections are shown. The scale bars
represent 10mm
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ketamine) NMDAR-antagonists (Figure 2A). The GluN2B-
selective antagonist ifenprodil prevented TrkB regulation
similar to DL-AP5 (Supplementary Figures S4A and B),
consistent with the coupling of GluN2B subunits of the
extrasynaptic NMDARs to excitotoxic pathways.2,29 Also
supporting the importance of the source of calcium, the
increase of intracellular calcium concentration with
thapsigargin, an inhibitor of the endoplasmic reticulum
Ca2þ -ATPase, or calcium ionophore A23187 could not
mimic the NMDA-induced TrkB regulation (Supplementary
Figure S4C). Our mixed cultures, grown in minimun essential
medium to reproduce the cellular brain environment and
containing a 27±4% of astrocytes, required NMDAR
overactivation with NMDA concentrations 410 mM for
TrkB regulation (Supplementary Figures S5A, left panel,
and S5B). In comparison, neuronal-enriched cultures in
neurobasal medium containing a 4±0.4% of astrocytes
presented a higher sensitivity for TrkB-FL downregulation
(Supplementary Figure S5B) and neuronal death
(Supplementary Figure S5C), probably reflecting reduced
glutamate uptake.
A kinetic analysis of TrkB regulation demonstrated that 2 h
of NMDA treatment significantly reduced the TrkB-FL
expression to 72±5% (P¼ 0.004; Figures 2B and C).
Stimulation over 4 and 8 h further decreased TrkB-FL to
45±2% (P¼ 0.0001) and 33±3% (P¼ 0.001), respectively.
Conversely, we observed a progressive increase in tTrkB
levels (Figure 2B, upper panel), which reached values of
219±30% (P¼ 0.01) and 304±39% (P¼ 0.006), relative to
untreated cultures 1 and 2h after NMDA stimulation,
respectively (Figure 2C). This increase was partially due to
the upregulation of TrkB-T1 (95 kDa; Figure 2B, middle
panel), which reached values of 196±18% (P¼ 0.01) 1 h
after NMDA stimulation, relative to untreated cultures, and
increased more gradually afterwards (Figure 2C). We
analyzed the cell specificity of TrkB regulation by immuno-
fluorescence of neuronal markers NeuN and bIII-tubulin, and
panTrkB (Figure 2D). Total TrkB was mainly detected in the
soma and dendrites of untreated neurons, also labeled with
NeuN (Figure 2D, panel a) or bIII-tubulin (Figure 2D, panel c).
After NMDA stimulation for 1 h, a condition that induced
prevalence of tTrkB over TrkB-FL (Figure 2B), neurons were
still labeled by panTrkB (Figure 2D, arrows), a result
resembling that obtained in the ischemic brain (Supplemen-
tary Figures S2C and D). Morphological changes character-
istic of excitotoxicity and typically preceding death,30 such as
dendritic focal swelling and the formation of varicosities, were
found in stimulated neurons (Figure 2D, panels b and d).
Mechanisms of TrkB regulation induced by
excitotoxicity. Transient ischemia modifies brain patterns
of alternative mRNA splicing.31 Therefore, we examined
changes in the relative mRNA levels of TrkB isoforms
after excitotoxic stimulation indicative of a modification of
mRNA splicing. Quantitative RT-PCR revealed that
TrkB-FL transcripts were significantly reduced to 59±5%
(P¼ 0.00001) and 43±12% (P¼ 0.04), compared with
untreated cells after 2 and 3 h of NMDA stimulation,
respectively (Figure 3a). Conversely, TrkB-T1 transcripts
were increased significantly after treatment and reached
values of 146±13% (P¼ 0.005) by 2 h of stimulation. We
concluded that excitotoxicity induced a progressive increase
in the ratio of TrkB-T1 to TrkB-FL mRNA.
We considered other possible mechanisms of TrkB regula-
tion, such as endocytic degradation of BDNF/TrkB complexes
that might be mediated by BDNF released after excitotoxic
stimulation.32 Compared with NMDA, BDNF treatment (1–4 h)
did not extensively modify TrkB levels, though it induced TrkB
tyrosine-kinase phosphorylation and activation (Figure 3b).
Quantitation confirmed a significant regulation of TrkB iso-
forms induced by NMDA compared with stable levels after
BDNF treatment, with only a small and transient increase of
TrkB-T1 at 1 h (Figure 3c). These results suggest that, in the
time window analyzed, BDNF-induced mechanisms did not
contribute to TrkB regulation by NMDA. As TrkB-interacting
proteins (e.g. NMDARs and kinase D-interacting substrate of
220 kDa/ankyrin repeat-rich membrane spanning (Kidins220/
ARMS))33 are calpain substrates,13,14,27 and this protease is
activated by excitotoxicity,16 we investigated the possible
contribution of calpain to TrkB-FL downregulation. The
NMDA-induced decrease in TrkB-FL was largely prevented
by the calpain inhibitor calpeptin, which had no effect on TrkB-
T1 upregulation (Figure 3d). We tested calpain activity and
calpeptin efficacy by analyzing the processing of a well-
characterized calpain substrate, FL brain spectrin (240 kDa),
which produces breakdown products of 150 and 145 kDa. In
contrast, lactacystin did not prevent TrkB-FL regulation,
although it increased p53 levels (Figure 3d), a proteasome
substrate. The contribution of calpain to Trk-FL downregula-
tion was quantified. Preincubation with calpeptin upon NMDA
treatment greatly restored TrkB-FL levels, which were
68±5% of those obtained in cells incubated only with
calpeptin, and significantly higher than those in NMDA-treated
neurons (39±3%; P¼ 0.0003, calpeptinþNMDA versus
NMDA; Figure 3e). A parallel comparison failed to show an
effect of calpain inhibition in TrkB-T1 regulation (212±26%
versus 222±56%, respectively). Collectively, these experi-
ments revealed a dual mechanism of TrkB regulation in
excitotoxicity; one major component was extensive calpain-
dependent processing of TrkB-FL, and the other element was
due to regulation of the relative TrkB-FL and TrkB-T1 mRNA
levels.
Characterization of TrkB-FL calpain processing. To
further characterize the TrkB-FL processing, we generated
a dual lentiviral vector that expresses an N-terminally
hemagglutinin (HA)-tagged TrkB-FL and GFP (LV-HA-TrkB-
FL/GFP) or two fluorescent proteins (LV-DsRed/GFP)34 in
the same neuron (Figure 4A). These genes were under the
control of synapsin promoters, which drove their efficient
neuro-specific co-expression.34 Immunostaining of cultures
infected with a low multiplicity of LV-HA-TrkB-FL/GFP
confirmed expression of the transducible genes. Compared
with non-transduced cells, an increase in TrkB was found
only in neurons that expressed GFP (Figure 4B). Immunoblot
analysis of cultures infected with increasing multiplicities of
LV-HA-TrkB-FL/GFP demonstrated augmented total TrkB-
FL levels compared with constant levels of endogenous
TrkB-FL in LV-DsRed/GFP-infected cells (Figure 4C).
Recombinant TrkB-FL receptors were processed after
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NMDA treatment and yielded fragment(s) that contained the
N-terminal HA-tag with a mobility of B95 kDa (Figure 4D).
Calpeptin prevented HA-TrkB-FL cleavage, demonstrating
that the processing of recombinant and endogenous
receptors was calpain-dependent.
We also analyzed in vitro processing of TrkB by purified
calpain (Figure 4E). Incubation of extracts containing HA-
TrkB-FL with calpain revealed that, contrary to TrkB-T1,
recombinant and endogenous TrkB-FL were sensitive to
cleavage. This result directly established TrkB-FL as a novel
calpain substrate and showed that cleavage occurred down-
stream but nearby the divergence point with TrkB-T1
sequence. This TrkB-FL fragment, together with TrkB-T1,
contributed to the increase of tTrkB detected by panTrkB in
NMDA-treated neurons (Figure 2B). In conclusion, calpain
processing generated a truncated TrkB-FL that lacked the
tyrosine-kinase domain and was strikingly similar to TrkB-T1.
Upregulation of TrkB-T1 in human stroke. To approach
the possibility that TrkB neuronal survival pathways are also
downregulated in human ischemia, we analyzed necropsies
from acute ischemic stroke patients, where we compared
infarcted cerebral cortex to equivalent regions in the
contralateral hemispheres. We characterized TrkB-T1 by
immunoblot and found very high levels in the ischemic area
compared with contralateral tissue, whereas similar levels of
other neuronal proteins (e.g. NSE) were found in both the
hemispheres (Figure 5A, left panel). Quantitation of these
results showed a mean increase of normalized TrkB-T1
levels of 4.8 times in the infarcted tissue versus the
contralateral hemisphere (Figure 5A, right panel), which
was not significant, probably because of inter-individual
variability, differences in time of tissue collection (2.5–7 h
postmortem), and small size of the sample analyzed (n¼ 3).
For TrkB-FL, we found heterogeneous levels in the control
tissues (Figure 5A, left panel) probably due to different levels
of spontaneous postmortem calpain activation taking place
early after death in infarcted and, more importantly, not
infarcted tissue.35 Accordingly, almost complete cleavage
of spectrin was observed in control and ischemic tissues.
To reproduce the instability of TrkB-FL in the postmortem
tissue, we analyzed the isoform levels in the brain of the rat
Figure 3 Two different mechanisms contribute to TrkB regulation in excitotoxicity. (a) Quantitative RT-PCR of TrkB-FL and TrkB-T1 mRNAs. Relative mRNA levels
(mean±S.E.M., n¼ 3 experiments) were established after normalization to 18S rRNA and comparison with untreated cells, which were arbitrarily assigned a value of 100%.
The effect of NMDA was assessed using a Student’s unpaired t-test (*Po0.05, **Po0.01, and ***Po0.001). Reverse regulation of isoform mRNAs producing a progressive
increase in the fraction of TrkB-T1 mRNA was observed. (b) Contrary to NMDA stimulation, treatment with BDNF (100 ng/ml) for 14 h induced TrkB activation, established by
phospho (p)-TrkB detection with p-TrkA (Tyr490)-specific antibodies, but no general modification of TrkB-FL, tTrkB, or TrkB-T1. (c) Quantitation of TrkB-FL and TrkB-T1 levels
in cultures treated with NMDA and BDNF showed that BDNF-induced mechanisms were not contributing to TrkB regulation induced by excitotoxicity. Levels of TrkB-FL and
TrkB-T1 (mean±S.E.M., n¼ 10 experiments) were compared with the levels in untreated neurons, which were arbitrarily assigned a value of 100%. Student’s unpaired t-test
was used to evaluate the differences between treated or untreated cultures (N.S., nonsignificant; *Po0.05, **Po0.01, and ***Po0.001). (d) TrkB-FL is processed by a
calpain-dependent mechanism during excitotoxicity. Cultures were preincubated with protease inhibitors lactacystin (20 mM) or calpeptin (10 mM) before NMDA treatment for
2 h. The processing of FL brain spectrin to produce characteristic breakdown products (BDPs) was used as a standard assay of calpain activity, whereas levels of p53 were
analyzed to confirm proteasome inhibition. (e) Quantitation of TrkB-FL revealed calpain-dependent processing as the major mechanism of NMDA-induced TrkB regulation.
Cultures were preincubated and treated with lactacystin or calpeptin as described above. Normalized TrkB-FL levels (mean±S.E.M., n¼ 8 experiments) in neurons treated
with NMDA, with or without protease inhibitors, were compared with the corresponding levels found in control neurons without NMDA, which were arbitrarily assigned a
value of 100%. Student’s unpaired t-test was used to evaluate the differences in the NMDA-treated cultures between those with or without calpain inhibitor preincubation
(N.S., nonsignificant; ***Po0.001)
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embryos kept at room temperature for different periods after
death (2–8 h; Figure 5B). Processing of TrkB-FL was fast
and largely parallel to that of spectrin, although the levels of
TrkB-T1 were more stable. This isoform could be still
detected by 8 h postmortem, a time point when TrkB-FL
and spectrin were already processed. These results suggest
that, in stroke, TrkB-FL downregulation induced by ischemia
can be only observed at the earliest postmortem times
(Figure 5A, patient 15), and that TrkB-T1 upregulation is not
related to spontaneous calpain activation. Next, we
performed immunohistochemistry of human infarcted cortex
and confirmed the increase in TrkB-T1 compared with the
very low levels found in the contralateral hemisphere
(Figure 5C). The identification of post-mitotic neurons
with NeuN antibodies revealed that TrkB-T1 upregulation in
stroke was mainly neuro-specific (Figure 5C) as
demonstrated before in the animal model (Figure 1A and
Supplementary Figures S2A and B). The heterogeneity of
NeuN levels in the ischemic region was suggestive of
neurodegeneration, which may be associated with TrkB-T1
upregulation.
Recovery of TrkB-FL/TrkB-T1 balance confers
neuroprotection against excitotoxicity. Dysregulation of
TrkB isoforms induced by excitotoxicity may contribute to
neuronal death and, therefore, reversion of these changes
Figure 4 Characterization of TrkB-FL as a calpain substrate. (A) Schematic diagram of lentiviral vectors LV-DsRed/GFP (encoding DsRed and GFP fluorescent proteins)
and LV-HA-TrkB-FL/GFP (coding for HA-TrkB-FL and GFP). The recombinant proteins are regulated by neuro-specific synapsin promoters (pSyn), and their sequences are
followed by woodchuck hepatitis post-transcriptional regulatory element (WPRE) for the enhancement of expression. LTR, long terminal repeat. (B) Double immunostaining
with panTrkB and GFP antibodies of cultures infected with a low multiplicity of LV-HA-TrkB-FL/GFP demonstrated increased TrkB levels in specific neurons co-expressing
GFP (arrowheads) compared with endogenous TrkB in uninfected neurons (arrows). Confocal microscopy images correspond to single sections. The scale bars represent
10mm. (C) Cultures infected with lentivirus LV-HA-TrkB-FL/GFP using increasing multiplicities of infection (m.o.i.) showed the expression of HA-TrkB-FL and the specific
increase of TrkB-FL total levels compared with LV-DsRed/GFP-infected cells. (D) Processing of recombinant HA-TrkB-FL expressed in LV-HA-TrkB-FL/GFP-infected neurons
(m.o.i.¼ 2) is induced by 2 h of NMDA treatment and produces N-terminally HA-tagged fragments. Cleavage is blocked by pre-incubation for 1 h with the specific calpain-
inhibitor calpeptin (10 mM). (E) In-vitro calpain processing of extracts prepared from neurons infected with LV-HA-TrkB-FL/GFP using purified calpain I (80 U/ml) directly
established TrkB-FL as a calpain substrate, in contrast to TrkB-T1, and suggested that cleavage yields a truncated TrkB-FL that is similar to TrkB-T1. The additional HA-TrkB-FL
fragment that was produced in vitro, with a mobility B110 kDa (left panel), may correspond to an intermediate product and was not observed in cultures subjected to
excitotoxicity
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would confer neuroprotection. To test this hypothesis, we
investigated the consequences in neuronal viability of an
increase in TrkB-FL expression. After LV-HA-TrkB-FL/GFP
infection, the combined levels of wild-type and recombinant
TrkB-FL were higher compared with the LV-DsRed/GFP-
infected cultures (Figure 6a), although both the TrkB-FL
forms were still processed by NMDA-activated calpain. This
increase only partially counteracted one of the mechanisms
of TrkB regulation induced by excitotoxicity and had no effect
on TrkB-T1 upregulation (Figure 6a) or neuronal viability
(Figure 6b). Next, we explored the effect of counteracting
the TrkB-T1 increase by using microRNAs (miRNAs). Five
double-stranded oligonucleotides (Supplementary Figure S6)
encoding pre-miRNAs specific for target sequences in TrkB-T1
mRNA 30-UTR (Supplementary Figure S7A) were used to
produce pcD/miT1 plasmids, which were initially tested in a
heterologous system (Supplementary Figure S7B). Plasmids
showing the highest efficiency in TrkB-T1 interference
Figure 5 TrkB-T1 isoform levels increase after stroke in human brain neurons. (A) Immunoblot analysis of TrkB-T1 expression in the cerebral cortex of three patients using
an isoform-specific antibody. A comparison of the infarcted cortex (I) with the corresponding area of the contralateral hemisphere (C) demonstrated a dramatic increase of
TrkB-T1 in the ischemic area, but similar levels of NSE in both regions. The postmortem time of tissue collection for each patient is indicated below the blot panels.
Heterogeneous TrkB-FL levels in the control tissue of the various patients were observed using a panTrkB antibody that recognized the FL isoform and the truncated forms of
the TrkB receptor (tTrkB). The processing of FL brain spectrin to produce breakdown products (BDPs) demonstrated the activation of this protease in necropsies
corresponding to both control and ischemic tissue. The histogram represents the quantitation of the normalized TrkB-T1 levels (mean±S.E.M., n¼ 3) in the infarcted tissue
compared with the contralateral hemisphere, arbitrarily assigned a value of 100%. Student’s unpaired t-test established that the observed differences were nonsignificant
(P¼ 0.1). (B) Demonstration of TrkB-FL cleavage in parallel to spontaneous calpain activation in normal brain tissue at different times after death. Individual Wistar rat
embryos (E18) were kept at ambient temperature for 2 to 8 h before dissection of brain cortices, which were then compared with tissue collected immediately after death. No
increase in TrkB-T1 levels was observed, showing that calpain activation and TrkB-T1 upregulation are not related processes. (C) Immunohistochemistry of tissue sections
corresponding to infarcted cerebral cortex or equivalent regions in the contralateral hemisphere confirmed the increased expression of TrkB-T1 in the ischemic area, mostly in
post-mitotic neurons labeled with a NeuN antibody. Heterogeneity of NeuN levels in the infarcted area is highlighted. Although neurons that have low TrkB-T1 levels are
strongly stained by NeuN (arrows), high TrkB-T1 levels are associated with neurons that have low NeuN expression (arrowheads). The scale bar represents 50mm
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compared with the pcD/miC control (pcD/miT1(2310) and
pcD/miT1(2178)) were chosen for further analysis.
To produce neuro-specific TrkB-T1 interference, these
pre-miRNAs were cloned under the control of a synapsin
promoter to produce lentiviruses LV-miT1(2178)/GFP
and LV-miT1(2310)/GFP (Figure 6c). Strong inter-
ference of basal TrkB-T1 expression was produced by
LV-miT1(2310)/GFP-infection, which was further increased
by mixed infection with LV-miT1(2178)/GFP, a virus having
only moderate effects by itself (Figure 6d). Interference was
specific for TrkB-T1 and not observed for TrkB-FL or other
proteins. Additionally, the combined infection with LV-miT1/
GFP viruses strongly prevented the TrkB-T1 upregulation
induced by excitotoxicity in LV-miC/GFP-infected cells
(Figure 6e). However, it had no effect on TrkB-FL
downregulation (Figure 6e) or neuronal viability (Figure 6f).
We reasoned that it might be necessary to simultaneously
counteract both the mechanisms of TrkB dysregulation to
protect neurons from excitotoxic damage. Therefore, we
generated another lentivirus that produced TrkB-FL and the
two more efficient TrkB-T1 pre-miRNAs (LV-HA-TrkB-FL/
2xmiT1) in the same neuron (Figure 7a). This virus strongly
interfered with basal TrkB-T1 expression and increased TrkB-
FL levels compared with untreated LV-DsRed/GFP-infected
cells (Figure 7b). Moreover, after NMDA stimulation, LV-HA-
TrkB-FL/2xmiT1 prevented TrkB-T1 upregulation and
induced higher TrkB-FL levels compared with LV-DsRed/
GFP-infected cultures (Figure 7b). We compared the effect
of double counteraction of TrkB dysregulation on neuronal
viability with respect to single strategies. The viability of
untreated cultures infected with lentiviruses LV-DsRed/GFP,
LV-HA-TrkB-FL/2xmiT1, LV-HA-TrkB-FL/GFP, LV-miC/GFP,
or LV-miT1/GFP was very similar (Supplementary Figure S8),
suggesting that an increase in TrkB-FL and/or a decrease in
TrkB-T1 did not enhance basal survival pathways. In contrast,
infected neurons responded differently to 2 h of NMDA
Figure 6 Effect of increased TrkB-FL expression or TrkB-T1 interference during excitotoxicity. (a) Time course of NMDA treatment in cultures transduced with LV-HA-
TrkB-FL/GFP (m.o.i.¼ 2) demonstrated higher levels of total TrkB-FL compared with LV-DsRed/GFP-infected cells. (b) Relative neuronal viability (mean±S.E.M., n¼ 6)
of cells infected and NMDA treated as above. Using Student’s unpaired t-test, no significant differences were found between cells infected with LV-HA-TrkB-FL/GFP
or LV-DsRed/GFP. (c) Schematic diagram of lentiviral vectors for neuro-specific interference of the TrkB-T1 isoform. Pre-miRNAs specific for target sequences in TrkB-T1
mRNA, starting at nucleotide 2178 or 2310, were cloned under the control of pSyn to produce viruses LV-miT1(2178)/GFP and LV-miT1(2310)/GFP (herein, LV-miT1/GFP).
Transcription of miRNAs was controlled by RNA polymerase II and was cell type-specific. Lentivirus LV-miC/GFP contains negative-control pre-miRNAs sequences.
(d) Efficient and specific interference of basal TrkB-T1 expression was obtained by double infection with LV-miT1(2178)/GFP plus LV-miT1(2310)/GFP (m.o.i.¼ 1 for each
virus) or LV-miT1(2310)/GFP with LV-miC/GFP (m.o.i.¼ 1 for each virus). No changes were observed for TrkB-FL or other analyzed proteins. (e) Double infection with
LV-miT1(2178)/GFP and LV-miT1(2310)/GFP strongly interfered with the TrkB-T1 upregulation that was induced by NMDA compared with cultures infected with LV-miC/GFP
(m.o.i.¼ 2). (f) Relative neuronal viability (mean±S.E.M., n¼ 6) of cells infected with LV-miT1(2178)/GFP and LV-miT1(2310)/GFP (m.o.i.¼ 1 for each virus), or
LV-miC/GFP (m.o.i.¼ 2), treated or not treated with NMDA. Student’s unpaired t-test revealed no significant differences in viability between cells infected with these viruses
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treatment. Neuronal viability was reduced by NMDA to
75±1% in LV-HA-TrkB-FL/2xmiT1-infected cells, a value
that was significantly higher than that obtained in cultures
infected with LV-DsRed/GFP (52±3%, P¼ 0.0001) or the
other viruses (Figure 7c). A time-course analysis in LV-HA-
TrkB-FL/2xmiT1-infected neurons demonstrated that the
greatest differences in the kinetics of neuronal death were
obtained during the initial period of excitotoxicity, though
neuronal viability was higher at the various times tested,
compared with LV-DsRed/GFP-infected cells (Figure 7d).
After 4 h of NMDA stimulation, the viability of LV-HA-TrkB-FL/
2xmiT1-infected cultures was 48±3%, a value significantly
higher than that found in the LV-DsRed/GFP-infected cultures
(27±2%, P¼ 0.0005). As protection was observed in LV-HA-
TrkB-FL/2xmiT1-infected neurons, we analyzed TrkB activity
finding high levels of phosphorylated TrkB-FL in untreated
cultures that decreased progressively over the time of NMDA
treatment similar to total TrkB-FL (Figure 7b). Therefore,
these results demonstrated that the dysregulation of
normal TrkB-FL/TrkB-T1 balance is an important mechanism
of neuronal death induced by excitotoxicity, and the
simultaneous increase in TrkB-FL expression and interfer-
ence of TrkB-T1 synthesis has a neuroprotective effect
against these insults.
Discussion
Excessive activation of NMDARs is central to degeneration
and death of the adult neurons in ischemia and other
disorders1 by mechanisms that are not completely under-
stood. Here, we unveiled a TrkB-FL/TrkB-T1 imbalance as
one neurodegeneration mechanism in ischemia. A dysregula-
tion of TrkB was observed in neurons of infarcted human brain
and rat neurons that were subjected to in vivo or in vitro
excitotoxicity. One of themechanisms contributing to the TrkB
regulation altered the physiological ratio of mRNAs encoding
for TrkB isoforms and favored the expression of TrkB-T1 over
TrkB-FL. Splicing and transcription are tightly coupled
processes, and splice-site selection is altered by changes in
chromatin structure,36 transcription rates,37 and promoter
identity and occupancy.38 As TrkB is a CREB-regulated
gene,9,10 the suppression of CREB by extrasynaptic NMDAR
Figure 7 Increased TrkB-FL expression together with TrkB-T1 interference confers neuroprotection against excitotoxicity. (a) Schematic diagram of lentivirus LV-HA-TrkB-
FL/2xmiT1, which was designed for the neuro-specific expression of recombinant HA-TrkB-FL simultaneously with the double interference of TrkB-T1 by miT1(2178) and
miT1(2310) pre-miRNAs (purple and violet boxes, respectively). (b) Time course of NMDA treatment in cultures transduced with LV-HA-TrkB-FL/2xmiT1 (m.o.i.¼ 2) showing
higher levels of total TrkB-FL and strong interference of TrkB-T1 both in basal and stimulated conditions compared with LV-DsRed/GFP infections. (c) Relative neuronal
viability (mean±S.E.M., n¼ 3) of cultures transduced with different viruses that modified the TrkB-FL/TrkB-T1 balance and stimulated with NMDA (2 h) are expressed as
percentages of the values obtained in untreated cells infected with the same virus (arbitrarily established as 100%). Cultures were infected with LV-HA-TrkB-FL/2xmiT1,
LV-DsRed/GFP, LV-HA-TrkB-FL/GFP, LV-miC/GFP (m.o.i.¼ 2), or LV-miT1(2178)/GFP, together with LV-miT1(2310)/GFP (m.o.i.¼ 1 for each virus). Student’s unpaired
t-test demonstrated statistically significant differences between cells infected with LV-HA-TrkB-FL/2xmiT1 or LV-DsRed/GFP, and treated with NMDA (***Po0.001). (d) Time-
course analysis of the effect of NMDA on neuronal viability after LV-HA-TrkB-FL/2xmiT1 infection (m.o.i.¼ 2). Relative neuronal viability (mean±S.E.M., n¼ 3) is expressed
as percentage of the value obtained in untreated LV-DsRed/GFP infected cells (arbitrarily established as 100%). Student’s unpaired t-test showed significant differences
between cells infected with LV-HA-TrkB-FL/2xmiT1 or LV-DsRed/GFP at different times of NMDA treatment (***Po0.001), which demonstrates a neuroprotective effect of the
simultaneous increase in TrkB-FL expression and the interference with TrkB-T1 synthesis
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stimulation2 may decrease TrkB transcription and shift the
splicing of TrkB precursor mRNA. However, we will need to
consider other possible mechanisms induced by excito-
toxicity. The second and major mechanism of TrkB regulation
was calpain processing of TrkB-FL, unveiled here as a new
calpain substrate. A detailed analysis of TrkB-FL truncation in
stroke patients was hampered by postmortem spontaneous-
calpain activation in non-infarcted tissue.35 However, in a
cellular model, wewere able to establish that calpain activation
by excitotoxicity generated a truncated TrkB-FL receptor
similar to TrkB-T1, which may act as an additional dominant-
negative protein. All together, the decrease of BDNF/TrkB
signaling will impact neuronal survival and brain function.
Ischemia also regulates other proteins critical to neuronal
survival related to TrkB. The scaffolding protein PSD-95,
which is central to NMDAR regulation, is cleaved by calpain,
together with GluN2A andGluN2B. This combined processing
results in a truncated NMDAR defective in pro-survival
signaling.13 Another example is Kidins220/ARMS,33,39 a
protein that interacts with NMDARs27 or ephrin and neuro-
trophin receptors39 and has a key role in regulating neuronal
survival in excitotoxicity and ischemia.27 The downregulation
of TrkB in addition to that of NMDARs and Kidins220/ARMS
implies some redundancy in the mechanisms of excitotoxic
death, both concerning the number of proteins involved in a
pathway and the existence of overlapping mechanisms
for some proteins. This redundancy suggests functional
relevance for the efficient silencing of specific pro-survival
signaling cascades during the excitotoxic response.
These results identify TrkB isoforms as potential therapeu-
tic targets for neuroprotection in ischemia and should be
considered for the rational design of therapies for stroke and
related disorders. An enhancement of BDNF/TrkB signaling
has been proposed as a possible treatment for stroke;19
however, this approach might only prevent the delayed death
of neurons still expressing TrkB-FL after stroke. Here, we
explored the recovery of the TrkB-FL/TrkB-T1 balance as a
novel therapeutic strategy in stroke. Using lentiviruses
capable of neuro-specific expression of recombinant proteins
and/or miRNAs, we demonstrated the need for a combined
strategy to increase TrkB-FL expression and TrkB-T1 inter-
ference to produce a significant and reproducible protection
from excitotoxic insults. The recovery of neuronal viability in
cultures infected with LV-HA-TrkB-FL/2xmiT1 was limited
by the calpain processing of recombinant HA-TrkB-FL and
the redundancy of excitotoxic mechanisms (i.e. other death
pathways remained active). Because of the complexity of the
excitotoxic process, we will need to design combined
strategies that counteract the regulation of different targets
that are important for neuronal survival.
Materials and Methods
Plasmids. Plasmid pRc-CMV-HA-TrkB-FL, provided by Y Barde (Biozentrum,
Basel, Switzerland), encodes rat TrkB-FL with a HA epitope inserted at the
N-terminus. Oligonucleotides 50-GGGGACGCCTGGATCCGCGTAGGGACACGC
ACTCTG-30 and 50-GACAAGGAGCGGCCGCCCGGGGTGAGGCAGTGC-30 were
used to introduce BamHI and NotI sites flanking this cDNA. Nucleotides mutated in
the TrkB-FL cDNA are in bold, and restriction sequences are underlined. This
BamHI–NotI cDNA fragment was sub-cloned, substituting DsRed in LV-DsRed/
GFP34 digested with the same enzymes to produce LV-HA-TrkB-FL/GFP. In this
dual lentiviral vector, synthesis of HA-TrkB-FL and GFP is under the control of
neuro-specific synapsin promoters and their sequences are followed by woodchuck
hepatitis post-transcriptional regulatory elements for expression enhancement.
miRNAs for the specific knockdown of rat TrkB-T1 expression were designed
using the RNAi-designer website from Invitrogen (Carlsbad, CA, USA). We selected
five different double-stranded oligonucleotides (see details in Supplementary
Figure S6) coding pre-miRNAs specific for target sequences in the 30-UTR of the
mRNA (Supplementary Figure S7A). These sequences were cloned into the
pcDNA6.2-GW/miRNA vector using a Block-iT PolII miR RNAi expression vector kit
(Invitrogen) to generate the pcD/miT1 plasmids. This kit also provided a pcDNA6.2-
GW/miR-negative control plasmid (herein pcD/miC). After preliminary evaluation of
interference efficiency in a heterologous system (Supplementary Figure S7B),
vectors suitable for neuro-specific TrkB-T1 interference were prepared by taking
advantage of the fact that miRNA transcription is controlled by RNA polymerase II
and is cell type-specific. Thus, the BamHI–XhoI fragments isolated from the pcD/
miT1 plasmids that produced efficient TrkB-T1 interference (pcD/miT1(2178)
and pcD/miT1(2310)) and pcD/miC were cloned into the lentiviral vector LV-GFP
(syn-syn-GFP)34 and digested with the same enzymes to produce LV-miT1(2178)/
GFP, LV-miT1(2310)/GFP, and LV-miC/GFP. We also generated plasmid pcD/
2xmiT1 for double TrkB-T1 interference by cloning the BamHI–XhoI fragment that
was isolated from pcD/miT1(2310) into pcD/miT1(2178) digested with BglII and
XhoI. Finally, we designed a vector suitable for double TrkB-T1 interference and
HA–TrkB-FL expression in the same neurons. We eliminated the GFP gene from
LV-HA-TrkB/GFP by first digesting with EcoRI and, because two NheI sites are
present in this plasmid, partial digestion with NheI afterwards. Annealed
oligonucleotides 50-CTAGCGTGGATGATCAAGGTGTGTCTTGTTAGTGGGTCTT
ATGTCTCGAGGTGGTG-30 and 50-AATTCACCACCTCGAGACATAAGACCCACT
AACAAGACACACCTTGATCATCCACG-30 were cloned into the EcoRI and NheI
sites to produce LV-HA-TrkB/oligo, in which we introduced unique BclI and XhoI
sites (underlined in the sequences). Then, we cloned the BamHI–XhoI fragment
from pcD/2xmiT1, which carried the two TrkB-T1 miRNAs, into LV-HA-TrkB/oligo
that was digested with BclI and XhoI to generate LV-HA-TrkB-FL/2xmiT1.
Primary neuronal culture. Primary cultures were prepared from the cerebral
cortex of 18-day-old Wistar rat embryos, and grown in minimun essential medium
(Invitrogen-Life Technologies, Carslbad, CA, USA) as described previously.12
As they are mixed cultures, we inhibited glial growth by adding AraC (10mM) after
7 DIV. When indicated, primary cultures were also grown in neurobasal medium
(Invitrogen-Life Technologies) with serum-free B-27 supplement. Cultures were
treated with different reactives at 14 DIV. Unless otherwise stated, NMDA (100mM)
and glycine (10 mM) were used for NMDAR overactivation. For protease inhibition,
cultures were pretreated with the indicated compound for 30 min before NMDA
addition, and the inhibitor remained in the medium for the duration of the NMDA
treatment. Infection of primary cultures with lentiviruses produced as described in
Supplementary Materials and Methods was performed at 7 DIV and proceeded until
14 DIV.13
Experimental model of cerebral ischemia. All animal procedures were
performed in compliance with the European Community Law 86/609/EEC and were
approved by the Consejo Superior de Investigaciones Cientı´ficas Committee.
Male Sprague-Dawley adult rats (275–300 g) were anesthetized, maintained, and
monitored during surgery for MCAO as described previously.12 The MCA was
ligated before its bifurcation into frontal and parietal branches. After complete
interruption of blood flow, both common carotid arteries were also occluded, and all
three arteries were maintained in this state for 60 min. Six hours after blood
reperfusion, animals were intracardially perfused with cold 4% paraformaldehyde
(wt/vol) in PBS, pH 7.4. Brains were post-fixed for 6 h at 4 1C and cryoprotected by
serial immersion in 10, 15, and 20% sucrose (wt/vol) in PBS for 6 h at 4 1C. Frozen
coronal sections (30 mm thick) were prepared using a cryostat (Leica, Wetzlar,
Germany). In this model, the characteristic changes of ischemic damage are limited
to the cortex, and the subcortical structures and basal ganglia are spared.
Human brain samples. This study was approved by the Vall d’Hebron
Hospital Ethics Committee (PR[HG]85/04), and informed consent was obtained
from relatives before autopsy. The study included three deceased patients
(two men) who had an ischemic stroke within the previous 4 days (range 24–96 h).
On autopsy and during macroscopic examination, an experienced neuropathologist,
guided with recent neuroradiology images, established the infarcted area in the
cerebral cortex, mainly by consistency and parenchyma color, and surgically
separated the gray matter. Brain tissue from equivalent regions in the ipsilateral
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(infarction) and contralateral hemispheres was collected within the first 7 h after
death, snap-frozen in liquid nitrogen, and stored at 80 1C for immunoblotting or
fixed with formalin for immunohistochemistry.
Immunoblot analysis. For human brain extracts, tissue was homogenized in
lysis buffer (50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 5 mM CaCl2, 0.05% Brij-35
(vol/vol), 0.02% NaN3 (vol/vol), and 1% Triton X-100 (vol/vol)) containing
protease inhibitors (1 mM phenylmethylsulfonyl fluoride and 7 mg/ml aprotinin).
Cortical cultures were lysed in RIPA buffer as described previously,12 and equal
amounts of protein (25–50mg) were analyzed by immunoblotting, using the primary
and secondary antibodies indicated in the Supplementary Information. Immuno-
complexes were detected with a Bioluminescence kit from Perkin-Elmer (Boston,
MA, USA). Densitometric analysis was performed with NIH Image analysis
software. The results were normalized to levels of NSE in the same samples
and are represented as relative values in reference to the values obtained in the
untreated cells.
Immunofluorescence. The immunofluorescence procedure was described
previously.13 Confocal images were acquired using a Radiance 2000 confocal
(BioRad, Hercules, CA, USA) coupled to an inverted Axiovert S100 TV microscope
(Zeiss, Oberkochen, Germany) with a 63x Plan-Apochromat oil immersion objective.
Immunohistochemistry. Frozen sections (12 mm) of human specimens
were prepared using a cryostat, post-fixed in ice-cold acetone for 15 min, and
washed in 0.05% Tween (vol/vol)-PBS. Sections were blocked with 10% BSA
(wt/vol), 0.3% (vol/vol) Triton X-100 (vol/vol) in PBS for 1 h at room temperature, and
incubated overnight at 4 1C with primary antibodies. After incubation with secondary
antibodies, sections were mounted on coverslips using Vectashield with DAPI
(Vector Laboratories, Burlingame, CA, USA) and analyzed with a fluorescence
microscope (Olympus IX71, Essex, UK) interfaced with an image analysis
system. Images were processed with ImageJ software (NIH). In the MCAO model,
Nissl (0.1 % (wt/vol) cresyl violet) staining permitted the identification of neocortex
ischemic tissue. Adjacent sections (30 mm) were processed for immunohisto-
chemistry as described previously.13 Sections were mounted in Fluoromount-G
solution (Southern Biotechnology Assoc., Birmingham, AL, USA) or stained with
Fluoro-Jade B (Chemicon, Temacula, CA, USA) according to manufacturer’s
instructions. Confocal images were acquired as described for immunofluorescence.
Calpain in vitro proteolysis. Protein extracts were prepared using RIPA
buffer containing 1 mM phenylmethylsulfonyl fluoride, 10mg/ml pepstatin, 10mg/ml
aprotinin, 1 mM EDTA, and 1 mM EGTA. Calpain I (80 U/ml) was added to diluted
extracts (50mg) supplemented with 5 mM DTT and 2.5 mM CaCl2, and incubated
30 min at 37 1C.
Statistical analysis. Graph data represent mean values and the S.E.M.
obtained from three or more independent experiments. Statistical significance was
performed using an unpaired t-test (Student t-test). P-values o0.05 were
considered statistically significant.
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